Q32 Bio Inc
Follow $QTTB
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $QTTB by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredsnapshot unavailable for QTTB. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is QTTB moving today?
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
QTTB overview
Related filings and maps
Congress activity in QTTB
No receipt-qualified Congressional disclosure is present for QTTB in the cached public ledger.
QTTB contract awards, year to date.
Public federal awards linked to this ticker.
QTTB lobbying filings, year to date.
Registered lobbying filings matched to Q32 Bio Inc.